🎗️Лента новостей
Онкология
FIRST PATIENT SITE OPENS: Burjeel Cancer Institute at Burjeel Medical City Launches World’s First Clinical Site for BioSapien’s MediChip™ Chemotherapy Platform
FIRST PATIENT SITE OPENS: Burjeel Cancer Institute at Burjeel Medical City Launches World’s First Clinical Site for BioSapien’s MediChip™ Chemotherapy Platform markets.businessinsider.com
Онкология
‘Why do I have this cancer?’ At CNIO, breast cancer research gets personal - Centro Nacional de Investigaciones Oncológicas
‘Why do I have this cancer?’ At CNIO, breast cancer research gets personal Centro Nacional de Investigaciones Oncológicas - CNIO
Онкология
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer Investing News Network
Онкология
Douglas Flora: Pleased to Present the Future of Humanizing Cancer Care Through AI at ACCC
Douglas Flora: Pleased to Present the Future of Humanizing Cancer Care Through AI at ACCC Oncodaily
Онкология
Blackstone and TPG-backed Hologic agrees deal for precision oncology firm Reveal Genomics
Blackstone and TPG-backed Hologic agrees deal for precision oncology firm Reveal Genomics PE Hub
Онкология
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research BioSpace
Онкология
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research BioSpace
Онкология
Brazilian biobank may help personalize cancer prevention in the public health system
A bank of biological samples from thousands of Brazilians could help the Unified Health System (SUS), which is public and free, identify people at higher risk of developing certain types of cancer. In the future, the SUS could offer these individuals more personalized prevention and screening strategies.
Онкология
ECOG-ACRIN announces a national trial of ivonescimab for first-line treatment of advanced biliary tract cancer
ECOG-ACRIN announces a national trial of ivonescimab for first-line treatment of advanced biliary tract cancer EurekAlert!
Онкология
Азеносертиб: медиана общей выживаемости при раке яичников с положительным статусом циклина E1 — 15,8 месяца
Азеносертиб: медиана общей выживаемости при раке яичников с положительным статусом циклина E1 — 15,8 месяца the Pharma Media